{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"115","value":"107"},{"comment":"Cannot report because none in dose level 2 had a partial response or complete response.","groupId":"OG001","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"DOR is measured from the time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is recorded first) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started), death, or, in the absence of progressive disease (PD), date of last assessment. The response rate was assessed by the Response Evaluation Criteria in Lymphoma (RECIL) 2017 criteria and reported along with a 95% confidence interval. Complete response is complete disappearance of all target lesions. Partial response is ≥30% decrease in the sum of longest diameters of target lesions but not a complete response. Disease progression is \\>20% increase in the sum of longest diameters of target lesions or appearance of a new lesion.","dispersionType":"Standard Deviation","groups":[{"description":"Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day on days 1-5 of each of six cycles.\n\nAvelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.","id":"OG000","title":"Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab"},{"description":"Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a second dose level of 2 mcg/kg/day on days 1-5 of each of six cycles.\n\nAvelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.","id":"OG001","title":"Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"From the time that response to therapy is first documented until progressive disease is observed or the subject is lost to follow-up or approximately 2 years.","title":"Mean Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Days"}